00:23 , Feb 3, 2017 |  BC Innovations  |  Targets & Mechanisms

Eating healthy

While pharma is still treading carefully in the field of autophagy, unsure of its use in cancer, Deerfield Management Corp. L.P. has decided the time is right to invest in the emerging translational opportunities. The...
07:00 , Apr 12, 2010 |  BioCentury  |  Strategy

Altheos Mines its Rho-lodex

After concluding that all the interesting new projects in the U.S. and Europe had been picked over, the founders of Altheos Inc. turned to Asia to find assets for in-licensing. Based on the strength of...
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Cancer ATG3 autophagy-related 3 homolog (ATG3); viral FLICE-like inhibitory protein (FLIP) Studies in mice and in cell culture suggest that triggering cell death with...
08:00 , Mar 2, 2009 |  BioCentury  |  Product Development

Wet AMD pipeline

Wet AMD pipeline Company Product Description Status Eyetech/Pfizer (NYSE:PFE) Macugen pegaptanib Pegylated oligonucleotide aptamer that binds to VEGF 165 Mkt Genentech (NYSE:DNA) Lucentis ranibizumab Humanized mAb fragment against VEGF-A Mkt QLT (TSX:QLT; NASDAQ:QLTI) Visudyne verteporfin...
07:00 , May 5, 2008 |  BioCentury  |  Product Development

Ace of BACE

Pharma companies have been working on beta secretase as a target for Alzheimer's disease for several years, but problems getting inhibitors across the blood-brain barrier have so far prevented them from getting into the clinic....
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Mecamylamine: Phase II start

This quarter, Athenagen will begin a double-blind, placebo-controlled, international Phase II trial in 330 patients. Athenagen Inc. , South San Francisco, Calif.   Product: Mecamylamine (ATG3)   Business: Ophthalmic   Molecular target: Nicotinic acetylcholine receptor...
08:00 , Feb 5, 2007 |  BC Week In Review  |  Clinical News

Mecamylamine: Phase I data

In a double-blind, placebo-controlled, U.S. Phase I trial in 80 healthy volunteers, ATG3 was safe and did not cause systemic side effects. The compound was dosed twice-daily for 14 days. Athenagen Inc. , South San...